• Sofdra™ (sofpironium) topical gel successfully launched in February 2025 to treat excessive underarm sweating
• Sofdra™ is the first and only new chemical entity approved by the US FDA to treat primary axillary hyperhidrosis
• Positive launch trends with 323.5% growth in Q4 prescription volumes driven by new patient acquisition and refill compliance

Botanix Pharmaceuticals Limited (ASX:BOT) is a rapidly growing commercial dermatology company based in Philadelphia and Phoenix (US). In February 2025, the Company successfully launched its lead product Sofdra™ (sofpironium) topical gel, 12.45% a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older. Sofdra is the first and only new chemical entity approved by the US FDA to treat primary axillary hyperhidrosis ('hyperhidrosis') and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition. Hyperhidrosis is a condition characterised by abnormally increased sweating, beyond what is necessary to regulate body temperature. This disproportionate sweat production results in a disabling medical condition with profound effects on the patient's quality of life. Hyperhidrosis affects work productivity, daily routine activities, emotional well-being and personal relationships. The market for Sofdra is large and underserved, with approximately 10 million patients in the US who have primary axillary hyperhidrosis, of which 3.7 million are actively seeking treatment. Positive launch trends are impressive, with total prescriptions (TRx) for Sofdra growing month over month and experiencing 323.5% growth in Q4 versus Q3, driven by new patient acquisition and refill compliance. Gross-to-net yield has also improved each month and was 23% at the end of June, due in part to the Botanix Fulfilment Platform, which continues to improve prior authorisation (PA) approval rates and the number of fully reimbursed prescriptions.

Botanix has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.